ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "outcomes"

  • Abstract Number: 2314 • 2017 ACR/ARHP Annual Meeting

    Monoarticular Juvenile Idiopathic Arthritis: A Unique Entity?

    Caterina Politi1, Vanessa Cecchin1, Fabio Vittadello1, Alessandra Meneghel2, Giorgia Martini1 and Francesco Zulian2, 1Department of Woman and Child Health, University of Padua, Padua, Italy, 2University of Padua, Department of Woman and Child Health, Padua, Italy

    Background/Purpose: Oligoarticular Juvenile Idiopathic Arthritis (oligoJIA) is the most common JIA subtype. According with the most recent classification criteria1, monoarticular JIA (monoJIA) is included in…
  • Abstract Number: 348 • 2017 ACR/ARHP Annual Meeting

    The Impact of Rheumatoid Arthritis-Sustained Remission on Patient´s Reported Outcomes Differs Accordingly to Each Particular Outcome

    Irazú Contreras-Yáñez1, Guillermo Guaracha2, César Sifuentes-Cantú3 and Virginia Pascual-Ramos4, 1Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Instituto Nacional de Ciencias Médicas y Nutrició, Mexico City, Mexico

    Background/Purpose: Sustained remission (SR) is the most desirable status in patients with rheumatoid arthritis (RA). For adoption by patients, SR should reflect symptom´s resolution and…
  • Abstract Number: 2453 • 2017 ACR/ARHP Annual Meeting

    Methotrexate Discontinuation from Combination Therapy with Adalimumab Is Not Associated with Inferior Outcomes at 6 Months

    Dimitrios A. Pappas1, Chitra Karki1, Ying Shan1, Jessica L. Suboticki2, Jenny Griffith3 and Joel Kremer4, 1Corrona, LLC, Southborough, MA, 2AbbVie Inc., Mettawa, IL, 3AbbVie Inc., North Chicago, IL, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Methotrexate is frequently administered in combination with biologics for the therapy of Rheumatoid Arthritis (RA) as it leads to superior outcomes compared to biologic…
  • Abstract Number: 713 • 2017 ACR/ARHP Annual Meeting

    Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus

    Konstantinos Tselios1, Dafna D Gladman2, Zahi Touma3, Jiandong Su4, Nicole Anderson2 and Murray Urowitz5, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Prolonged clinical remission is a desirable, though rare outcome in systemic lupus erythematosus (SLE). We recently showed that low disease activity (LDA) state confers…
  • Abstract Number: 2608 • 2017 ACR/ARHP Annual Meeting

    Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers

    Chiara Tani1, Miguel Martin-Cascon2, Mériem Belhocine3, Roberta Vagelli1, Chiara Stagnaro4, Guillermo Ruiz-Irastorza5, Nathalie Costedoat-Chalumeau3 and Marta Mosca1, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Barakaldo, Spain, 3Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, 4Rheumatology Unit, University of Pisa, PISA, Italy, 5Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain

    Background/Purpose: there is no consensus on the use of Tacrolimus (TAC) in patients with SLE; clinical studies on TAC, including all the RCT, are mostly…
  • Abstract Number: 781 • 2017 ACR/ARHP Annual Meeting

    A Patient Based Reliability Exercise of Omeract Ultrasound Definitions in Giant Cell Arteritis

    Valentin S. Schäfer1, Stavros Chrysidis2, Christian Dejaco3, Christina Duftner4, Annamaria Iagnocco5, George A. W. Bruyn6, Greta Carrara7, MA D'Agostino8, Eugenio De Miguel9, Andreas P Diamantopoulos10, Ulrich Fredberg11, Wolfgang Hartung12, Alojzija Hočevar13, Tanaz A. Kermani14, Matthew J. Koster15, Tove Lorenzen16, Pierluigi Macchioni17, Marcin Milchert18, Uffe Møller Døhn19, Chetan Mukhtyar20, Cristina Ponte21, Sofia Ramiro22, Carlo Alberto Scirè23, Lene Terslev24, Kenneth J. Warrington15, Bhaskar Dasgupta25 and Wolfgang A. Schmidt26, 1Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, 2Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, 3Rheumatology and Immunology, Medical University Graz, Graz, Austria, 4Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, 5Academic Rheumatology Unit, Università degli Studi di Torino, Torino, Italy, 6Rheumatology, MC Groep, Loenga, Netherlands, 7Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, 8Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, 9Medicine, Universidad Autonoma Madrid, MADRID, Spain, 10Martina Hansens Hospital, Bærum, Oslo, Norway, 11Diagnostic Centre, Silkeborg Regional Hospital, 8600 Silkeborg, Denmark, 12Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, 13Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 14Rheumatology, University of California Los Angeles, Los Angeles, CA, 15Rheumatology, Mayo Clinic, Rochester, MN, 16Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, 17Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, 18Pomeranian Medical University, Szczecin,, Szczecin, Poland, 19Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, 20Norfolk and Norwich University Hospital, Norwich, United Kingdom, 21Rheumatology Department, Hospital de Santa Maria - Centro Hospital Lisboa Norte, Lisbon, Portugal, 22Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 23Italian Society for Rheumatology, Milan, Italy, 24Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 25Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Westcliff-on-Sea, United Kingdom, 26Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany

    Background/Purpose: To test the reliability of recently established consensus-based ultrasound definitions for normal and vasculitic temporal and axillary arteries in patients with giant cell arteritis…
  • Abstract Number: 2683 • 2017 ACR/ARHP Annual Meeting

    Factors Associated with Disease Progression in Early-Diagnosed Pulmonary Arterial Hypertension Associated with Systemic Sclerosis

    Carina Mihai1, Milos Antic2, Rucsandra Dobrota3, Diana Bonderman4, Harbajan Chadha-Boreham5, J. Gerry Coghlan6, Christopher Denton7, Martin Doelberg5, Ekkehard Gruenig8, Dinesh Khanna9, Vallerie McLaughlin10, Ulf Müller-Ladner11, Janet E. Pope12, Daniel M Rosenberg5, James R Seibold13, Madelon C Vonk14 and Oliver Distler15, 1Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 2University Hospital Zurich, Zurich, Switzerland, 3Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria, 5Actelion Pharmaceuticals Ltd., Alschwil, Switzerland, 6National Pulmonary Hypertension Service, Royal Free Hospital, London, United Kingdom, 7Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, 8Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany, 9Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, 10Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, 11Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, 12Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 13Scleroderma Research Consultants LLC, Litchfield, CT, 14Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 15Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), and its diagnosis requires right heart catheterization (RHC). The DETECT study developed…
  • Abstract Number: 923 • 2017 ACR/ARHP Annual Meeting

    Can Education Mitigate the Effect of Poverty on Total Knee Replacement (TKR) Outcomes?

    Susan M. Goodman1, Bella Y. Mehta2, Meng Zhang3, Jackie Szymonifka4, Iris Navarro-Millán5, Joseph T. Nguyen3, Yuo-Yu Lee3, Mark P. Figgie6, Michael L. Parks6, Shirin A. Dey4, Daisy Crego4, Linda A. Russell1, Lisa A. Mandl1 and Anne R. Bass1, 1Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery/Columbia University Mailman School of Public Health, New York, NY, 3Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 6Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY

    Background/Purpose:   Health outcomes after total knee replacement (TKR) are generally worse for patients from high poverty neighborhoods. Whether education mitigates the effect of poverty…
  • Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting

    Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study

    Ted R. Mikuls1, TC Cheetham2, Gerald D. Levy3, Nazia Rashid4, Kimberly Low5, Brian W Coburn6, Kenneth Saag7, Lang Chen8 and Jeffrey R. Curtis9, 1Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, 3Internal Medicine/Rheumatology, Kaiser Permanente Southern California, Downey, CA, 4Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey, CA, 5Kaiser Permanente Southern California, Panorama City, CA, 6Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 7Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 8University of Alabama at Birmingham, Birmingham, AL, 9Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose:   Allopurinol is a cornerstone therapy in gout management.  Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…
  • Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting

    Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study

    Kimberly Morishita1, Audrea Chen2, Cherry Mammen1, Angelyne Rivera3 and David Cabral1, 1BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 2Medicine, University of British Columbia, Vancouver, BC, Canada, 3Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…
  • Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting

    Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time

    Paul Studenic1, Stephan Blüml1, Holger Bang2, Daniela Sieghart1, Daniel Aletaha1, Helmuth Haslacher3, Josef S. Smolen1,4 and Günter Steiner1, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Orgentec Diagnostika GmbH, Mainz, Germany, 3Medical University Vienna, Department of Laboratory Medicine, Vienna, Austria, 4Department of Internal Medicine, Hietzing Hospital, Vienna, Austria

    Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…
  • Abstract Number: 1299 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Nathaniel Harris1, Amanda M. Eudy2 and Megan E. B. Clowse2, 1Duke University School of Medicine, Durham, NC, 2Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC

    Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is…
  • Abstract Number: 1317 • 2017 ACR/ARHP Annual Meeting

    Obstetric Outcomes in Women with Rheumatoid Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011

    Shweta Kishore1, Varun Mittal2, Venkataraman Palabindala3, Shradha Ahuja3 and Vikas Majithia1,4, 1Division of Rheumatology, University of Mississippi, Jackson, MS, 2Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, 3Division of Hospital Medicine, University of Mississippi, Jackson, MS, 4Jackson VA Medical Center and University of Mississippi, Jackson, MS

    Background/Purpose: Fertility is reduced in patients with Rheumatoid Arthritis (RA) due to unknown cause. Few studies mostly involving single center cohorts have addressed pregnancy outcomes…
  • Abstract Number: 1391 • 2017 ACR/ARHP Annual Meeting

    Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients

    Evan Choate1, Gurjit S. Kaeley2, Jenny Brook3, John Fitzgerald4, David Elashoff5 and Veena K. Ranganath6, 1David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 2Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, 3Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, 4David Geffen School of Medicine, Division of Rheumatology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, 5David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, 6Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Rheumatoid Arthritis (RA) disease activity outcomes are used for treatment decisions (ie. DAS28-ESR). Surgically operated joints (SOJ) are assumed not to respond to therapy…
  • Abstract Number: 2603 • 2016 ACR/ARHP Annual Meeting

    Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone

    Ara H. Dikranian1, Rubaiya Mallay2, Mike Marshall3, Megan Francis-Sedlak3 and Robert J. Holt4,5, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Suncoast Internal Medicine Consultants and Largo Med Center, Largo, FL, 3Horizon Pharma USA, Inc, Lake Forest, IL, 4Medical Affairs, Horizon Pharma, Inc, Lake Forest, IL, 5College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL

    Background/Purpose: Patients with RA have previously demonstrated significant differences in morning stiffness (MS), a debilitating symptom of RA, and other disease measures with delayed release…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology